Unraveling pathological mechanisms in neurological disorders: the impact of cell-based and organoid models

Introduction

Cell-based models, including embryonic stem cells (ESCs), tissue-derived mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs), have become an increasingly popular area of research showing promise in new treatments and providing fundamental knowledge of pathologies. Cell-based models have been utilized to understand the safety and determine the molecular mechanisms of new drug therapies and to model diseased states (Mittal et al., 2019). These cell-based models can provide a greater understanding and in-depth appreciation for various diseases as they allow us to observe the progression of disease and real-time response to treatment. There are also challenges in acquiring biopsies from live patients. With respect to the central nervous system, it is arguably unethical and dangerous to obtain multiple biopsies from the same patient to understand the progression of disease. Therefore, cell-based models allow us to begin to understand the progression from healthy to pathological tissue in numerous diseases.

The advancement of cell-based models has not only allowed us to recapitulate the normal physiology but has also allowed us to begin to replicate components of neurological diseases. These neurological diseases include amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), Alzheimer’s disease (AD), and autism spectrum disorder (ASD) (Eshraghi et al., 2018; Mittal et al., 2019). As we begin to understand more of the molecular underpinnings and genetic differences of these diseases, we are better able to model the pathophysiology in cell-based models using new technologies such as single-cell imaging and gene editing (Horvath et al., 2016). The cell-based models of these diseases have necessarily advanced beyond two-dimensional (2D) cell cultures and include new cell-based assays in drug discovery and pathophysiology studies. This includes iPSCs, three-dimensional (3D) cultures of multiple cell lines, and organ-on-a-chip systems (Horvath et al., 2016). Replicating individual diseased cell lines and combining them with functional models of other cells into a 3D model best mimics the diseased state that exists in vivo. Molecular techniques have allowed us to understand genetic and epidemiological changes in addition to the regulation of proteins and transcription factors present in the disease. To best utilize cell-based models, incorporation and modeling of accessory structures, extracellular fluids, and non-sensory cells are essential. This review aims to impart on recent advances in the cell-based modeling of neurological disorders (including ASD, PD, AD, and ALS) while discussing the pathophysiology of these diseases and the development of novel therapeutics.

Database Search Strategy

References were compiled using PubMed, Cochrane Library, and Medline databases. The search included articles published up to 2021 in this narrative review. A wide array of keywords and their abbreviated versions were used, including Alzheimer’s Disease (AD), Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease (PD), autism spectrum disorder (ASD), cell-based models, organ-on-a-chip, induced pluripotent stem cells (iPSCs), human pluripotent stem cells (hPSCs), mesenchymal stem cells (MSCs), pathophysiology, etiology, drug treatment, therapeutics, and human embryonic stem cells (hESCs). Peer-reviewed articles were selected that: (1) emphasized advancement of cell-based and organoid models, and (2) highlighted a unique finding or obstacle in modeling neurological disorders.

Cell-Based Models

Mimicking neurological disorders using an in vitro model has been the goal of researchers for many years. Such models, if designed to mimic the in vivo condition, allow us to better understand pathophysiological mechanisms and molecular alterations as well as test the efficacy of various drugs before advancing to in vivo trials (Figure 1). In vitro models offer the advantage of reduced animal use, higher throughput, reduced cost, and better control of the physical and chemical environment.

2D models

Protocols have been developed to establish human embryonic-like stem cells through the reprogramming of somatic cells using stem cell technologies. The basis for this technology is rooted in a study by Yamanaka et al who used a retroviral vector to exogenously express four transcription factors, Oct3/4, Sox2, Klf4, and c-myc, that drove somatic fibroblasts back to a state of pluripotency (Takahashi and Yamanaka, 2006). Some of the first iPSC models generated were of neurogenic diseases, including ALS, PD, and AD (Dimos et al., 2008; Soldner et al., 2009; Israel et al., 2012). An alternative cell-based model of neurological disorders includes direct harvesting of ESCs from the blastocyst and differentiating to the desired cell line. However, these models are much more difficult to harvest and generate compared to iPSCs (Simmacher et al., 2019).

How to cite this article: Langlie J, Mittal R, Finberg A, Bencie NB, Mittal J, Omidian H, Omidly Y, Eshraghi AA (2022) Unraveling pathological mechanisms in neurological disorders: the impact of cell-based and organoid models. Neural Regen Res 17(10):2131-2140.

Supplementary material

Supplementary data are available at Neural Regen Res online.

References

https://doi.org/10.4103/1673-5374.335836

Date of submission: August 5, 2021

Date of decision: September 18, 2021

Date of acceptance: November 2, 2021

Date of web publication: February 28, 2022

From the Contents

Introduction 2131
Database Search Strategy 2131
Cell Based Models 2132
Future Directions 2139

Introduction

Stem cells, including embryonic stem cells (ESCs), tissue-derived mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs), have become an increasingly popular area of research showing promise in new treatments and providing fundamental knowledge of pathologies. Cell-based models have been utilized to understand the safety and determine the molecular mechanisms of new drug therapies and to model diseased states (Mittal et al., 2019). These cell-based models can provide a greater understanding and in-depth appreciation for various diseases as they allow us to observe the progression of disease and real-time response to treatment. There are also challenges in acquiring biopsies from live patients. With respect to the central nervous system, it is arguably unethical and dangerous to obtain multiple biopsies from the same patient to understand the progression of disease. Therefore, cell-based models allow us to begin to understand the progression from healthy to pathological tissue in numerous diseases.

The advancement of cell-based models has not only allowed us to recapitulate the normal physiology but has also allowed us to begin to replicate components of neurological diseases. These neurological diseases include amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), Alzheimer’s disease (AD), and autism spectrum disorder (ASD) (Eshraghi et al., 2018; Mittal et al., 2019). As we begin to understand more of the molecular underpinnings and genetic differences of these diseases, we are better able to model the pathophysiology in cell-based models using new technologies such as single-cell imaging and gene editing (Horvath et al., 2016). The cell-based models of these diseases have necessarily advanced beyond two-dimensional (2D) cell cultures and include new cell-based assays in drug discovery and pathophysiology studies. This includes iPSCs, three-dimensional (3D) cultures of multiple cell lines, and organ-on-a-chip systems (Horvath et al., 2016). Replicating individual diseased cell lines and combining them with functional models of other cells into a 3D model best mimics the diseased state that exists in vivo. Molecular techniques have allowed us to understand genetic and epidemiological changes in addition to the regulation of proteins and transcription factors present in the disease. To best utilize cell-based models, incorporation and modeling of accessory structures, extracellular fluids, and non-sensory cells are essential. This review aims to impart on recent advances in the cell-based modeling of neurological disorders (including ASD, PD, AD, and ALS) while discussing the pathophysiology of these diseases and the development of novel therapeutics.

Database Search Strategy

References were compiled using PubMed, Cochrane Library, and Medline databases. The search included articles published up to 2021 in this narrative review. A wide array of keywords and their abbreviated versions were used, including Alzheimer’s Disease (AD), Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease (PD), autism spectrum disorder (ASD), cell-based models, organ-on-a-chip, induced pluripotent stem cells (iPSCs), human pluripotent stem cells (hPSCs), mesenchymal stem cells (MSCs), pathophysiology, etiology, drug treatment, therapeutics, and human embryonic stem cells (hESCs). Peer-reviewed articles were selected that: (1) emphasized advancement of cell-based and organoid models, and (2) highlighted a unique finding or obstacle in modeling neurological disorders.

Cell-Based Models

Mimicking neurological disorders using an in vitro model has been the goal of researchers for many years. Such models, if designed to mimic the in vivo condition, allow us to better understand pathophysiological mechanisms and molecular alterations as well as test the efficacy of various drugs before advancing to in vivo trials (Figure 1). In vitro models offer the advantage of reduced animal use, higher throughput, reduced cost, and better control of the physical and chemical environment.

2D models

Protocols have been developed to establish human embryonic-like stem cells through the reprogramming of somatic cells using stem cell technologies. The basis for this technology is rooted in a study by Yamanaka et al who used a retroviral vector to exogenously express four transcription factors, Oct3/4, Sox2, Klf4, and c-myc, that drove somatic fibroblasts back to a state of pluripotency (Takahashi and Yamanaka, 2006). Some of the first iPSC models generated were of neurogenic diseases, including ALS, PD, and AD (Dimos et al., 2008; Soldner et al., 2009; Israel et al., 2012). An alternative cell-based model of neurological disorders includes direct harvesting of ESCs from the blastocyst and differentiating to the desired cell line. However, these models are much more difficult to harvest and generate compared to iPSCs (Simmacher et al., 2019).
The differentiation of iPSCs into neurons with various neurotransmitter phenotypes provides new opportunities to model central nervous system (CNS) diseases (Tao and Zhang, 2016). With the generation of iPSC models and recent developments in the generation of organoids, we are beginning to see tissue-based modeling of many neurodegenerative disorders including ASD, PD, ALS, and AD. 2D in vitro models characteristically allow for high throughput screening before advancing to a more complex model. However, limitations to 2D in vitro models include the limited doubling potential of cell lines, polarity, and the possibility of infection of the culture medium. In addition, 2D models do not closely mimic the natural organization of tissues.

3D models

Research into the field of modeling neurodegenerative diseases has focused on 3D organoid models of the brain, where they can transplant multiple cell lines of generated iPSCs into one model (Di Lullo and Kriegstein, 2017; Benito-Kwiecinski and Lancaster, 2020). There have been multiple cerebral models generated by preliminary derivation of the pituitary, hypothalamic, and cerebral cortex. A progressing to much more complex models that include all six cortical layers of the forebrain (Qian et al., 2016). Models have even recapitulated the overall pattern of brain organoid generation through the use of iPSCs and ESCs to generate whole-brain or specific regional organoids. Figure 2 highlights the overall pattern of brain organoid generation through the use of iPSCs and ESCs to generate whole-brain or specific regional organoids.

**Matrigel matrix model of 3D organoid generation**

A majority of models utilize serum-free culture to generate embryoid body-like aggregates. These are induced with forebrain inductive signals, growth factors, and extracellular matrix proteins to induce growth of the brain (Mariani et al., 2012; Kadoshima et al., 2013; Ilieva et al., 2018). The generated neurospheres are subsequently embedded in Matrigel that is terminally differentiated within a spinning bioreactor.

To begin, iPSCs are cultured for roughly 5 days until they become embryoid bodies through germ layer differentiation. The embryoid bodies are then further differentiated into neurospheres through neural induction. These neurospheres are subsequently embedded within a Matrigel hydrogel droplet. Spontaneously due to the embedding process, budding neurospheres generate fluid-filled cavities that are similar to in vivo ventricles. The neuroepithelium then begins to migrate outwards, generating cerebral layers consisting of layered neural progenitor cells. With subsequent exposure to retinoic acid, cerebral organoids are able to self-organize through self-patterning mechanisms to populations of neural progenitors including radial glia, expanding the cerebral structures. As the progenitor cells are grown within a spinning bioreactor, radial glia differentiate and migrate to form the cortical plate consisting of neurons, the subventricular zone consisting of basal radial glia and intermediate progenitors, and the ventricular zone, named for its location adjacent to the ventricle, composed of apical radial glia. The neuronal migration depends on a layer of Cajal-Retzius cells and the outward migration is regulated by the protein reelin secreted by the latter cells (Hescheler, 1998). This technique to generate CNS cerebral organoids is highlighted in Figure 3.

**Neuronal layering method of brain organoid development**

Pluripotent stem cells (PSCs) include embryonic stem cells (ESCs) and induced PSCs (iPSCs). ESCs can be generated from the blastocyst, and iPSCs can be reprogrammed from somatic cells. These cell lines can then be transplanted into microdevices to allow for differentiation of the cortical layers in culture. This can allow the researcher to mimic the layers of cell lines that are present in normal physiology. Protocols have been developed for the generation of cortical identity with neuralization occurring spontaneously. However, exogenous factors, including WNT inhibitors, prevent the differentiation of the ectoderm and mesoderm, and are often used in combination with BMP inhibitors of TGF-beta inhibitors to maintain a neural identity (Chiaradia and Lancaster, 2020). Generation of brain organoids often has overlapping approaches, but the general goal is to successfully mimic the in vivo physiology of the normal cortical structures.

**Advantages of 3D models**

Cerebral organoids allow us to advance beyond our in vitro cell culture models toward more closely mimicking normal physiology. To limit the amount of animal use, these structures can give us an intermediate bridge between in vivo models and 2D in vitro cultures. 3D models allow for a higher sense of complexity when compared to their 2D counterparts. There is a need for expansion of 3D organoid models as they do not require the extensive maintenance and cost of in vivo models, can be scaled to a higher level, and allow for greater control of the generated models to tease out underlying mechanisms. The 3D model can then be advanced to an in vivo model.

**Cell-Based Models of Common Neurological Disorders**

In this section, we discuss cell-based models of common neurological diseases and highlight the new technology of organoid-based and 3D models in the field of neurodegenerative diseases. We will conclude by highlighting the limitations, challenges, and solutions of 3D organoid models.

**Autism spectrum disorders: cell-based models**

ASD comprises an array of neurodevelopmental deficits that affect how a person communicates and interacts with others. This spectrum includes the previously characterized diagnoses of Asperger’s disorder, pervasive developmental disorder, childhood disintegrative disorder, and autistic disorder (Cheng et al., 2020). The key drivers of pathogenesis indicate early changes in neurogenesis and network formation within the nervous system (Acb and Muotri, 2015). While transgenic and knockout mouse models have been created, they typically target only one gene. With a heterogeneous population of possible candidate genes and a known pleomorphic disorder such as autism, it is not feasible to model the disease in its entirety in an animal model (Acb and Muotri, 2015). The advancement of iPSCs that allow the generation of a library of stem cell models from any individual has paved the way to replicate disease and patient-specific disorders. These models can help to understand the molecular and cellular mechanisms driving ASD.

**2D in vitro models of autism spectrum disorders**

The hope for the development of iPSCs in the field of autism is to generate patient-specific iPSCs to replace nonfunctional neurons in the CNS (Acb and Muotri, 2015). However, in generating iPSCs, it is difficult to understand which phenotypes represent the disease state as there is a deficit of knowledge about the underlying mechanisms driving neuronevolution in ASD. One study showed that beyond genetic mutations, ASD is modulated by some environmental and external factors such as cytokines that mediate neurogenesis in the womb, specifically heat shock proteins (Lin et al., 2014). There are known gene mutations generated in iPSCs that are correlated with...
brain organoid models have been generated to model exposure to Zika virus microcephaly (Vianna et al., 2018; Wheeler, 2018; Santi et al., 2021). Thus, associated with autism including neonatal infection of Zika virus, leading to intellectual disability, and speech and language development. These deficits often manifest the initial signs for a diagnosis of ASD. These mutations can cause hyperexcitability of neurons and offer new electrophysiological targets for the treatment of known genetic causes of ASD (Fink et al., 2018).

ASD has no clear etiology, and the genetic heterogeneity provides a limited understanding of the pathways. However, a large number of the genes that have been linked to autism share common functions including neuronal transmitter pathways (Trobiani et al., 2018; BiCarlo et al., 2020), neuron adhesion, dendrite size, and spineogenesis (Desphande et al., 2017; Gouder et al., 2019), calcium-regulated signaling (Schmunk et al., 2017), neuronal hyperexcitability (Fink et al., 2018; Deneault et al., 2019), and junction molecules (Fiorentino et al., 2016; Lutz et al., 2020).

Many of the models generated have focused on syndromic autism. However, nonsyndromic autism, known as classic autism, has also been replicated in an iPSC model. Autism typically presents with poor social responsiveness and delayed development of motor skills (Griess-Oliveira et al., 2020). Recent models have attempted to mimic nonsyndromic autism, but few have shown success.

Given that autism comprised a spectrum of disorders, two alternative 2D models have been proposed to model the disease. The first model is to use a single patient who demonstrates a characteristic clinical manifestation of autism, and subsequently monitor the differences in the molecular and cellular signatures compared to a healthy and matched control. Although this pathway does not fully encompass the heterogeneity of autism, if repeated, it would allow for identification of a group of target genes and pathways. An alternative solution is to use a larger subset of patients presenting with idiopathic ASD and generate organoids from these patients, allowing us to distinguish pathological findings from controls in a 3D model (Ilieva et al., 2018). Rather than creating a representative iPSC model of autism, it may be more useful to first generate a library of ASD iPSCs with the capability to tease out the molecular pathways affected by different individuals and identify specific phenotypes. This could be followed by advancing to a larger scale organoid model. The key cell-based models of autism spectrum disorder and related disorders are reviewed in Table 1, highlighting the mutation, cell line, and objective of the model.

Brain-specific organoids can also be generated of disorders that induce syndromic forms of ASD with known genetic causes. These include Angelman syndrome, which has a high comorbidity with autism and shares a common genetic basis with some forms of ASD (Khati and Man, 2019; Sun et al., 2019). Key 3D models of ASD are reviewed in Table 2.

Amyotrophic lateral sclerosis: cell-based models

Background of autism spectrum disorders

As a paralytic and neurodegenerative disorder, ALS is characterized by the sequential degeneration of motor neurons in the CNS (Brown and Al-Chalabi, 2017). There are no treatments to stop or reverse the effects of the disease. Therefore, most patients have a mean survival of three to five years following initial diagnosis (van Es et al., 2017). Around 10% of diagnosed cases are due to familial-inherited forms of ALS, while the remaining 90% of diagnoses are from sporadic cases. Various molecular pathways underlying the genetic heterogeneity of the disease have been implicated, encompassing around twenty genes. These genes code for cellular signaling defects, surrounding non-neuronal cell dysfunction, and abnormal protein aggregation (Van Ittemme et al., 2017). SOD-1 mutant familial ALS is the most common subset of genetic mutations in ALS patients, but specific treatments have yet to be fruitful (Fujimori et al., 2018). Rodent models have been generated of ALS, yet these models are not easily translatable due to the complexity of the human CNS. One study showed that the lifespan of ALS mice could be improved by transplanting neural progenitor cells derived from human iPSCs, a possible method of regeneration to be exploited in future human clinical trials (Kondo et al., 2014).

2D models of amyotrophic lateral sclerosis

Other than organoid-based models, iPSC models of ALS appear to be ideal for mimicking human-specific neuronal and glial cell dysfunction. As multiple etiologies of ALS have been discovered, there have also been multiple cell-based models of ALS generated in recent years. In one study, iPSCs were created from patients with ALS and subsequently differentiated into glial cell types and motor neurons specifically affected in ALS (De Stefano et al., 2008). These cells could have future uses in elucidating the mechanisms of disease and serving as screening models for novel therapeutics. A more recent study modeled a common subtype of ALS, ALSB8, using patients that presented with a vesicle associated membrane protein associated protein B (VAPB) mutation (Mitne-Neto et al., 2011). When compared to controls, mutant ALS8 neurons displayed reduced protein levels of VAPB in an iPSC model, thereby implicating a mechanism of defective transport in the pathogenesis of ALS. As the number of iPSC-ALS models expands, we expect new drug discoveries in the field, including the identification of novel therapeutic agents based on libraries of cultured in vitro ALS models (Fujimori et al., 2018). The key cell-based models of ALS are reviewed in Table 3, highlighting the pathogenetic and mechanistic findings discovered through the models.

3D models of amyotrophic lateral sclerosis

It appears that advancement from an iPSC model to an organoid model that can recapitulate ALS on a tissue-level is not far from reality. A recent study successfully generated an organoid of motor neurons from stem cells, thereby generating a model of the principal cell affected in amyotrophic lateral sclerosis patients (Kawada et al., 2017). Functional human neuromuscular junctions of sensorimotor neurons in organoid models have also been developed from gene-edited neurons created to harbor familial ALS mutations as well as derived from native ALS iPSC lines (Pereira et al., 2021). These models mimic the impairment present at the neuromuscular junction in ALS.

There has also been a successful generation of microglia that innately develop in a cerebral organoid model, adding to the complexity of the model needed to appropriately represent ALS in vivo (Ormel et al., 2018). As we continue to...
**Table 1 | Neurological Cell-based iPSC models for Autism spectrum disorder**

| Neurologic disorder | Model and mutation | Purpose and findings of model | Reference |
|---------------------|--------------------|-------------------------------|-----------|
| Review of iPSC modeling of autism spectrum disorder | Neuron derived iPSCs – NRXN1, NLGN3, NLGN4X, SH3 domain, Shank2, and SHANK3 | • This review highlighted multiple models that have been generated from patients with diagnosed ASD. | Prilutsky et al., 2014 |
| Neurodevelopmental disorders (iPSCs) | Fibroblast derived iPSCs – 16p11.2 deletion or duplication | • Modeling deletions and duplications of the 16p11.2 region in patients presenting with neurodevelopmental disorders. | Deshpande et al., 2017 |
| Autism spectrum disorder (iPSC) | Neuron derived iPSCs – Dup15q (15q11.31-q13) syndrome | • DUP15q syndrome presented with language impairments, seizures, and motor deficits with patients often meeting the criteria for ASD. | Fink et al., 2018 |
| Autism spectrum disorder (iPSC) | Neuron derived iPSCs – GLI3/KIF21A and EHMT2/UBE2I mutations | • iPSC-derived glutamatergic neuronal cells were generated to study the complex relationship of penetrant and weaker polygenic risk variants of ASD. | Deneault et al., 2019 |
| Autism spectrum disorder (iPSC) | Neuron derived iPSCs – SHANK3 mutations | • SHANK3 is a gene involved in the pathophysiology of ASD. | Goudet et al., 2019 |
| Autism spectrum disorder (iPSCs) | Neuron derived iPSCs – various mutations | • The proteomic analysis yielded those high functioning individuals with ASD had dysregulation of genes involved in protein synthesis as well as modulation of neurotransmission and synapse genes. | Griesi-Oliveira et al., 2020 |

**Table 2 | Neurological and organoid models for autism spectrum disorder and related diseases**

| Neurologic organoids and 3D culture | Structures replicated | Reference |
|-------------------------------------|----------------------|-----------|
| Microcephaly organoid generation | • An organoid was created using human iPSCs to mimic structures affected in the pathophysiology of microcephaly. • These structures included the cerebral cortex, a structure often implicated in the underlying pathology of ASD. | Lancaster et al., 2013 |
| Zika virus exposed brain organoids | • Miniaturized spinning bioreactors were utilized to generate brain-region specific organoids from human iPSCs to model exposure to Zika virus. | Qian et al., 2016 |
| Angelman syndrome organoid generation | • Generating an organoid model of Angelman syndrome, a disorder with high rates of comorbidity and similar genetic disposition to ASD. • The organoids successfully modeled the developmental timeline of human brains with the successful recapitulation of the generation of inhibitory and stimulatory neurons. | Sun et al., 2019 |
| Neuropsychological brain organoids review | • Review highlighting the field of modeling brain structures and its focus on the generation of 3D neuronal organoid models. | Benito-Kwiecinski and Lancaster, 2020 |

**Table 3 | Neurological cell-based iPSC models for amyotrophic lateral sclerosis**

| Neurologic disorder | Model and mutation | Purpose and findings of the model | Reference |
|---------------------|--------------------|-------------------------------|-----------|
| Amyotrophic lateral sclerosis (iPSCs) | Fibroblast derived iPSCs – familial ALS | • One of the early models of ALS where fibroblast-derived iPSCs were differentiated into fibroblast-derived iPSCs into functional motor neurons which are destroyed in the pathogenesis of the disease. | Dimos et al., 2008 |
| Amyotrophic lateral sclerosis (iPSCs) | Fibroblast derived iPSCs – familial ALS – ALS8 | • iPSCs were derived from a patient with ALSB, a form of ALS, and their non-carrier siblings. | Mitne-Neto et al., 2011 |
| Amyotrophic lateral sclerosis (iPSCs) | Fibroblast derived iPSCs – sporadic ALS – multiple subtypes | • It was discovered that vesicle-associated membrane protein-associated protein B (VAPB) was reduced in ALS8-derived motor neurons. • VAPB levels may play a role in familial ALS as well as other forms of ALS. | Adler et al., 1997; Fujimori et al., 2018 |

ALS: Amyotrophic lateral sclerosis; ALS8: amyotrophic lateral sclerosis 8; iPSC: induced pluripotent stem cell; VAPB: vesicle-associated membrane protein-associated protein B.
expand cerebral organoids and increase their complexity, we may potentially reach a representational model of ALS needed to elucidate its etiology and develop a targeted therapy (Vieira de Sa et al., 2021). The key 3D models of ALS and related motor neuron disorders are reviewed in Table 4.

### Table 4: Neurologic 3D and organoid models for amyotrophic lateral sclerosis and related motor neuron dysfunction

| Neurologic organoids and 3D culture | Structures replicated | Reference |
|------------------------------------|----------------------|-----------|
| Motor neuron model | Researchers generated an organoid of motor neurons from stem cell-derived neurons, the principal cell affected in ALS patients. | Kowada et al., 2017 |
| Amyotrophic lateral sclerosis and motor neuron model | Successful development of motor neuron organoids containing functional human NMsIs. | Pereira et al., 2021 |
| 3D models | Organoid cultures were generated from ALS CNS disorders, which were edited to harbor familial ALS mutations. | |
| | Both models showed impairment at the neuromuscular junction. | |
| | This model may be essential to more accurately and comprehensively model the NMI. | |

#### Parkinson’s disease: cell-based models

**Background of Parkinson’s disease**

PD is a neurodegenerative disorder of movement that displays the pathognomonic death of dopaminergic neurons of the substantia nigra. There is an increased incidence of PD in association with aging, as it is most commonly observed in elderly populations. Clinical presentations of PD include tremor, bradykinesia, and rigor, three pathognomonic symptoms. PD is in sporadic forms of PD, as well as obtaining live neurons in vivo (Zhang et al., 2017).

**2D in vitro models of Parkinson’s disease**

Modeling PD through a stem cell-based approach is difficult, given that multiple phenotypes of the disease exist, and each requires a separate cell line. Methods current at that time. However, various entities have been used to model both sporadic and familial phenotypes may be key to (i) elucidating novel molecular pathways, and (ii) understanding the regulation that plays into the Parkinson’s phenotype. PD is a unique CNS disorder, whose characteristics do not arise until the late stages of the disease. This adds to the complexity of modeling the disease as aging dopaminergic cell lines are difficult to model. Early 3P55 modeling of PD was shown to successfully create dopaminergic neurons, yet the key cellular phenotypes indicative of PD failed to emerge (Soldner et al., 2009). Those changes may not have emerged due to inadequate aging of the model, or because the changes were too subtle to be detected by methods current at that time. However, various entities have been used to model the cell stressors experienced by PD neurons, including oxidative stress, growth factor deficiencies, mitochondrial toxins, and environmental toxins (Ryan et al., 2013), or even accelerating aging through the modulation of progerin, a protein known to be involved in premature aging (Miller et al., 2013).

Most models have focused on familial cases of PD including SNCA (Byers et al., 2011), Devine et al., 2011; Mazzulli et al., 2013; Chung et al., 2013; and LRRK2 (Nguyen et al., 2012; Sanchez et al., 2012; Reinhardt et al., 2013). These models have shown that dopaminergic neurons in PD are adversely affected and susceptible to oxidative stress with LRRK2 mutations (Ilang et al., 2012). The most common mutation in PD is the mutation of p.G2019S-LRRK2 in dopaminergic neurons (Nguyen et al., 2011). Mutations in alpha-synuclein (SNCA), the primary component of the hallmark features of Lewy bodies, have also been mimicked in vitro models (Xu et al., 2015). Triplication of SNCA is known to cause an aggressive and fully penetrant form of PD with dementia (Devine et al., 2011).

To gain a better understanding of the interplay between the abnormal and normal structures in patients with PD, it is essential to move beyond a 2D model and into an organoid-based system. The key cell-based models of Parkinson’s disease are reviewed in Table 5, highlighting novel cell-based models.

**3D models of Parkinson’s disease**

The human midbrain is an essential structure to replicate in PD organoids, as many of the hallmark characteristics of the disease including Lewy bodies and Lewy dendrites arise there (Schwamborn, 2018; Kwak et al., 2020; Nichols et al., 2020). Motor neurons have shown the potential of generation of midbrain organoid generation while mitigating batch variability (Nichols et al., 2020). Standardized approaches have successfully replicated the human midbrain and have been used to study toxin-induced PD (Kim et al., 2010; Smits and Schwamborn, 2020). However, there is a continual need to expand the models to mimic both the genetic and environmental dispositions that facilitate the development of PD (Schwamborn, 2018). Researchers have successfully modeled idiopathic PD, through the generation of IPSCs, by transduction with Sendai viral vectors, and have directed differentiation into an organoid-like structure. They found that the expression of multiple neuron markers varied when comparing the healthy organoids with those of the PD organoid. Notably, there was a significant difference in beta-amyloid-presentative neurons, and those neurons from the PD organoid did not express tyrosine hydroxylase (TH) (Chlebanowska et al., 2020).

Spontaneous LRRK2 mutations have been generated in 3D organoid systems, giving new possibilities of generating in vivo physiology and architecture to be used in the disease modeling research of PD. We have included a representative figure from an article by Kim et al. (2019) showing the generation of brain organoids from a specific LRRK2 model of PD (Figure 4).

Recently, it has been proposed that signs of pathology are evident in the gut of PD patients far before any neurological deficits are evident. Therefore, it has been suggested to study PD using a multi-organ culture that includes different brain regions beyond the midbrain, including organoids of the intestine and gut as well as immune cells (Reiner et al., 2021). As organoids become more developed and ornate, there is hope that further elucidating the pathogenesis of organoids could allow for more effective treatments for PD. Key organoid and 3D models of PD are reviewed in Table 6, highlighting the structures that could be replicated in vitro.

**Alzheimer’s disease: cell-based models**

**Alzheimer’s disease background**

AD has been notoriously difficult to diagnose early due to its high prevalence in elderly populations, making it difficult to distinguish between normal age-related cognitive decline and pathological loss of memory. AD is hypothesized to be caused by altered processing of the amyloid-beta precursor that is thought to function in the formation of pathologic plaques in the cerebral. A definitive diagnosis requires a post-mortem examination of the brain to identify amyloid-beta and tau protein deposits that make up the plaques and tangles pathognomonic of AD, protein deposits that were first identified by a group of psychiatrists over a hundred years ago (Goedert and Spillantini, 2000). However, using current techniques for linking the disease, physicians can diagnose AD with 95% accuracy based on clinical evaluation and history alone (Desikan et al., 2009). Approximately 95% of cases of AD are found to be sporadic, with only 5% of cases of familial AD diagnosed annually (Desikan et al., 2009). The most common early symptoms of AD are a gradual loss of episodic memory and loss of short-term memory, eventually leading to dementia and dramatic loss of cognitive function (Mucke, 2009).

**2D in vitro models of Alzheimer’s disease**

As elusive as the disease remains, it has been essential to create cell-based models, including IPSCs, to understand the currently unknown etiology of AD. The present limitations in understanding the underlying etiology have been difficulties in differentiating neurons already in their permanently differentiated state in sporadic forms of AD, as well as obtaining live neurons from patients (Israel et al., 2012). In a transgenic mouse model of AD, neural stem cells with upregulated BDNF were implanted and showed marked improvement in cognition (Blument-Jones et al., 2009). However, this study has yet to yield translatable protocols to human models.

Familial forms of the patient-derived IPSCs, with increased phosphorylated tau, higher amyloid-beta 42, and Aβ pathology, have been created in several models (Yagi et al., 2020; Shi et al., 2012; Kondo et al., 2013; Mahairaki et al., 2014; Penney et al., 2020). These models have been used for drug screening including beta-secretase inhibitors and gamma-secretase inhibitors (Yahata et al., 2011), have elucidated the increased sensitivity of AD neurons to cell death (Duan et al., 2014), have implicated mutations in APPV717I as causative for amyloid-beta accumulation and tauopathies in AD (Muratore et al., 2014), and shown that PSEN1 (Sproul et al., 2014) can play a role in the pathogenesis of AD. PSEN1 encodes the catalytic subunit of the gamma-secretase that cleaves the amyloid precursor protein. Without functional gamma-secretase, APP protein can accumulate within neurons due to improper degradation. A study successfully mimicked the elevated amounts of amyloid-beta peptide and created the pathogenic deposition of AP peptide in vitro (Israel et al., 2012). Models have since advanced to mimic the disruption of synaptic plasticity present in AD through extracellular forms of tau and amyloid-beta proteins (Hu et al., 2018). Moreover, even been used to study the protective mechanisms that aid the development of familial Alzheimer’s disease (Maloney et al., 2014). The key cell-based models of AD are reviewed in Table 7.
3D models of Alzheimer's disease
Recent organoid models and organ-on-a-chip models have emerged of AD, allowing greater elucidation of the etiology, physiological representation for drug screening, and increased mimicking of the actual disease. Two forms of 3D cultures have been created in the modeling of AD, including neuronal cultures and organoid cultures. Choi et al. (2014) generated 3D differentiated familial AD neuronal cultures showing that beta and gamma secretase-inhibitors inhibit amyloid-beta and tau protein pathology. Gonzalez et al. (2018) recently generated a model of AD cerebral organoids from familial AD patients as well as iPSCs derived from individuals with Down Syndrome patient-derived iPSCs. This model showed the pathologic accumulation of amyloid-beta peptides and created structures that closely resembled amyloid plaques (Gonzalez et al., 2018).

Now, models are attempting to use multi-tissue organoid-based models including astrocytes, oligodendrocytes, microglia, and neurons. These models more closely mimic the pathology of AD, recapitulating axonal cleavage resulting from neurotoxic activities, microglial recruitment, tau hyperphosphorylation, neuroinflammatory activity, release of nitrous oxide with deleterious effects on AD astrocytes and neurons, and β-amyloid aggregation (Park et al., 2018; Papaspyroupolou et al., 2020). This model and other key 3D and organoid models of AD are reviewed in Table 8.

Challenges, limitations, and solutions in generating neurologic and central nervous system organoids
To recapitulate neurological disorders, it is essential to generate reproducible protocols that can generate brain organoids with minimal variability. It has been shown that the current neurological models suffer from batch syndrome leading to significant variability in the regions as well as the quality of the models produced (Renner et al., 2017; Ilieva et al., 2018).

Another limitation is that current brain organoid models have difficulty progressing and maturing in their differentiation (Lancaster et al., 2013). In vivo, there is a time-dependent differentiation of the brain, with the primary generation of deeper layers and the subsequent development of the upper cortical layers later during the brain's development (Harris et al., 2015). Models that rely on the self-organization of the organ have led to variable results in terms of size and structures produced in the organoid. However, some of this has been overcome through differentiating stem cells in vitro and generating neurons in layers to mimic the different differentiation points that create a mature brain (Gaspard et al., 2008; Shi et al., 2012).

Recent organoid models and organ-on-a-chip models have generated a model of AD cerebral organoids from familial AD neuronal cultures showing that beta and gamma secretase-inhibitors inhibit amyloid-beta and tau protein pathology. Gonzalez et al. (2018) recently generated a model of AD cerebral organoids from familial AD patients as well as iPSCs derived from individuals with Down Syndrome patient-derived iPSCs. This model showed the pathologic accumulation of amyloid-beta peptides and created structures that closely resembled amyloid plaques (Gonzalez et al., 2018).

Now, models are attempting to use multi-tissue organoid-based models including astrocytes, oligodendrocytes, microglia, and neurons. These models more closely mimic the pathology of AD, recapitulating axonal cleavage resulting from neurotoxic activities, microglial recruitment, tau hyperphosphorylation, neuroinflammatory activity, release of nitrous oxide with deleterious effects on AD astrocytes and neurons, and β-amyloid aggregation (Park et al., 2018; Papaspyroupolou et al., 2020). This model and other key 3D and organoid models of AD are reviewed in Table 8.

Challenges, limitations, and solutions in generating neurologic and central nervous system organoids
To recapitulate neurological disorders, it is essential to generate reproducible protocols that can generate brain organoids with minimal variability. It has been shown that the current neurological models suffer from batch syndrome leading to significant variability in the regions as well as the quality of the models produced (Renner et al., 2017; Ilieva et al., 2018).

Another limitation is that current brain organoid models have difficulty progressing and maturing in their differentiation (Lancaster et al., 2013). In vivo, there is a time-dependent differentiation of the brain, with the primary generation of deeper layers and the subsequent development of the upper cortical layers later during the brain's development (Harris et al., 2015). Models that rely on the self-organization of the organ have led to variable results in terms of size and structures produced in the organoid. However, some of this has been overcome through differentiating stem cells in vitro and generating neurons in layers to mimic the different differentiation points that create a mature brain (Gaspard et al., 2008; Shi et al., 2012).

Some iPSC models require feeder cells that have a limited lifespan in culture. These cells also increase the risk of the introduction of infection to the cell culture media and lead to difficulty in mimicking the precise culture conditions between batches (Lancaster et al., 2013; Yoon et al., 2019). However, many iPSC lines now can be grown in Matrigel, providing sufficient signaling molecules to allow for successful culture without the need for feeder cells. Matrigel is a sterile substance and therefore, significantly reduces the risk of infection and allows for greater homogeneity between batches.

Organoid models of the brain that rely on self-organization have recently combined new techniques and biomaterials such as orbital shakers, spinning bioreactors, and microfluidics to overcome barriers of random neural patterning as well as allow for more homogenous models with sufficient perfusion (Kadoshima et al., 2013; Lancaster et al., 2013; Qian et al., 2016).

To progress current organoid models of the brain, limitations that do not allow for complete vascularization of the organoid need to be addressed. Insufficient maturation of neurons leads to insufficient oxygen and nutrient supply due to vascularization limits (Lancaster et al., 2013; Di Lullo and Kriegstein, 2017). Incomplete vascularization does not allow for the complete generation of the blood-brain barrier, limiting the applicability of drug treatment studies in organ-on-chip models (Muh et al., 2015).

However, incomplete vascularization has recently been addressed in both 3D models and organ-on-a-chip with successful and robust vascularization. One of the first techniques to overcome this challenge came through the ectopic expression of human ETS variant 2 (ETV2) through genetically engineered hESCs, contributing to a complex vascular-like network in human cortical...
Table 5 | Neurological cell-based iPSC models for Parkinson's disease

| Neurologic disorder | Model and mutation | Purpose and findings of the model | Reference |
|---------------------|--------------------|----------------------------------|-----------|
| Parkinson's disease | Fibroblast derived iPSCs – SNCA tripllication | • iPSCs harboring an alpha-synuclein gene (SNCA) triplication were generated from a patient with PD. | Byers et al., 2011 |
| Parkinson's disease | Gauchoer disease | • Functional loss of glucocerebrosidase in iPSC-derived neurons leads to accumulation of alpha-synuclein and aggregation-dependent neurotoxicity in lysosomes. | Mazzulli et al., 2011 |
| Parkinson's disease | Fibroblast derived iPSCs – FOXA2 mutation | • Demonstrating alpha-synuclein inhibits the normal activity of glucocerebrosidase, contributing to the pathogenesis of sporadic synucleinopathies including idiopathic PD. | Schwamborn et al., 2013 |
| Parkinson's disease | Fibroblast derived iPSCs – LRRK2 mutation | • The model utilized iPSC cells harboring triplication of SNCA, which causes a fully penetrant, aggressive form of Parkinson’s disease with dementia in vivo. | Devine et al., 2011 |
| Parkinson's disease | Fibroblast derived iPSCs – ANXA1 mutation | • Mutated LRRK2-G2019S iPSCs demonstrated the increased generation of alpha-synuclein protein and increased expression of oxidative stress-response genes. | Nguyen et al., 2011 |
| Parkinson's disease | Fibroblast derived iPSCs – SNCA triplication | • The model utilized iPSC cells harboring triplication of SNCA, which causes a fully penetrant, aggressive form of Parkinson’s disease with dementia in vivo. | Devine et al., 2011 |
| Parkinson's disease | Fibroblast derived iPSCs – SNCA triplication | • Demonstrated that differentiated midbrain dopaminergic neurons harboring SNCA triplication generated twice the normal amount of alpha-synuclein protein. | Devine et al., 2011 |
| Parkinson's disease | Fibroblast derived iPSCs – G2019S-LRRK2 mutation | • The model was used to test novel therapeutics that lower levels of alpha-synuclein. | Devine et al., 2011 |
| Parkinson's disease | Fibroblast derived iPSCs – G2019S-LRRK2 mutation | • The model was able to reverse the pathologic phenotypes of the mutated alpha-synuclein neurons in vitro with a small molecule. | Devine et al., 2011 |
| Parkinson's disease | Fibroblast derived iPSCs – Parkin mutations | • The model utilized iPSC cells harboring triplication of SNCA, which causes a fully penetrant, aggressive form of Parkinson’s disease with dementia in vivo. | Devine et al., 2011 |
| Parkinson's disease | Fibroblast derived iPSCs – SNCA triplication | • The model utilized iPSC cells harboring triplication of SNCA, which causes a fully penetrant, aggressive form of Parkinson’s disease with dementia in vivo. | Devine et al., 2011 |
| Parkinson's disease | Fibroblast derived iPSCs – SNCA triplication | • Mutated LRRK2 proteins impaired chaperone-mediated autophagy (CMA) in lysosomes and resulted in poor protein degradation. | Drenstein et al., 2013 |
| Parkinson's disease | Fibroblast derived iPSCs – G2019S-LRRK2 mutation | • Mutated LRRK2-G2019S neurons impaired the midbrain dopaminergic neurons and induced oxidative stress, nitrosative stress, and accumulation of ER-associated degradation. | Drenstein et al., 2013 |
| Parkinson's disease | Fibroblast derived iPSCs – G2019S-LRRK2 mutation | • Phenotype rescue in PD neurons could be achieved through correction of the LRRK2-G2019S mutation and idiopathic PD. | Reinhart et al., 2013 |
| Parkinson's disease | Fibroblast derived iPSCs – G2019S-LRRK2 mutation | • Ectopic expression of the TXNIP gene increased the expression of oxidative stress-response genes. | Reinhart et al., 2013 |
| Parkinson's disease | Fibroblast derived iPSCs – SNCA triplication | • Highlighting the importance of the generation of personalized brain organoids to mimic this “two-hit hypothesis.” | Schwamborn et al., 2013 |
| Parkinson's disease | G2019S-LRRK2 Parkinson's disease organoid | • The model utilized LRRK2-G2019S neurons to generate 3D midbrain PD organoids to mimic the age-induced modeling of PD. | Kim et al., 2019 |
| Parkinson's disease | Neurotrophic factor and Modeling Parkinson’s disease | • The model utilized LRRK2-G2019S neurons to generate 3D midbrain PD organoids to mimic the age-induced modeling of PD. | Kwak et al., 2020 |
| Parkinson's disease | Midbrain organoids | • Midbrain organoids with homogenous dopaminergic neuron distribution and similar in vivo cellular composition were used to replicate neurotoxin-based PD via 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. | Nickels et al., 2020 |
| Parkinson's disease | Parkinson's disease organoid | • The midbrain organoid generated included multiple glio-glial cells such as oligodendrocytes and astrocytes. | Nickels et al., 2020 |
| Parkinson's disease | Parkinson's disease organoid and 3D culture | • The model utilized midbrain neural floor plate progenitors cells to generate 3D organoids of the human midbrain with the LRRK2-G2019S mutation. | Smits et al., 2019 |
| Parkinson's disease | Parkinson's disease organoid and 3D culture review | • Mutated organoids showed a decrease in the complexity and quantity of dopaminergic neurons. | Smits and Schwamborn, 2020 |
| Parkinson's disease | Parkinson's disease organoid and 3D culture review | • The model utilized midbrain neural floor plate progenitors cells to generate 3D organoids of the human midbrain with the LRRK2-G2019S mutation. | Smits and Schwamborn, 2020 |
| Parkinson's disease | Parkinson's disease organoid and 3D culture | • Mutated organoids showed a decrease in the complexity and quantity of dopaminergic neurons. | Smits and Schwamborn, 2020 |
| Parkinson's disease | Parkinson's disease organoid and 3D culture review | • The first successful generation of a midbrain organoid model of idiopathic PD. | Chliebanowska et al., 2020 |
| Parkinson's disease | Parkinson's disease organoid and 3D culture review | • Mononuclear blood cells were used to generate iPSCs and differentiated into an organoid-like model. | Chliebanowska et al., 2020 |
| Parkinson's disease | Parkinson's disease organoid and 3D culture review | • PD neuronal cells showed varied expression levels of LIM homeobox transcription factor-alpha in early development and modified tyrosine hydroxylase levels in late development. | Chliebanowska et al., 2020 |
| Parkinson's disease | Parkinson's disease organoid and 3D culture review | • Highlighting the need for multi-organ systems, encompassing multiple brain regions, immune cells, the gut, and intestines, to study Parkinson’s disease. | Reiner et al., 2021 |
| Parkinson's disease | Parkinson's disease organoid and 3D culture review | • The model found that thiol-oxidoreductase (TXNIP) plays a key role in the generation of LRRK2-associated PD. | Reiner et al., 2021 |
| Parkinson's disease | Parkinson's disease organoid and 3D culture review | • Highlighting the importance of the generation of personalized brain organoids to mimic this “two-hit hypothesis.” | Reiner et al., 2021 |
| Parkinson's disease | Parkinson's disease organoid and 3D culture review | • The model found that thiol-oxidoreductase (TXNIP) plays a key role in the generation of LRRK2-associated PD. | Reiner et al., 2021 |
| Parkinson's disease | Parkinson's disease organoid and 3D culture review | • The model found that thiol-oxidoreductase (TXNIP) plays a key role in the generation of LRRK2-associated PD. | Reiner et al., 2021 |
| Parkinson's disease | Parkinson's disease organoid and 3D culture review | • The model found that thiol-oxidoreductase (TXNIP) plays a key role in the generation of LRRK2-associated PD. | Reiner et al., 2021 |

ANXA1: Annexin A1; CADPS2: calcium dependent secretion activator 2; CMA: chaperone mediated autophagy; CPNE8: Copine 8; ER: endoplasmic reticulum; iPSC: induced pluripotent stem cell; LRRK2: leucine rich repeat kinase 2; MAP7: microtubule associated protein 7; PD: Parkinson’s disease; SNCA: synuclein alpha; UHRF2: ubiquitin like with phd and ring finger domains 2.

Table 6 | Neurological 3D models for Parkinson’s disease and related neurodegenerative models

| Neurologic organoids and 3D culture | Structures replicated | Reference |
|------------------------------------|----------------------|-----------|
| Parkinson's disease organoid review | • A potential therapeutic target in PD may lower the stress response. | Schwamborn, 2018 |
| G2019S-LRRK2 Parkinson's disease organoid | • Identifying early pathogenic markers of PD including ER stress, nitrosative stress, and accumulation of ER-associated degradation. | Kim et al., 2019 |
| Neurotrophic factor and Modeling Parkinson’s disease | • Specific models of genetic models can advance therapeutic discovery in PD. | Nickels et al., 2020 |
| Midbrain organoids for modeling Parkinson’s disease | • Description of a novel time-efficient protocol for the generation of toxin-induced midbrain PD organoids that addresses the concerns of batch variability and the presence of a necrotic inner core of many midbrain organoids. | Smits et al., 2019 |
| Parkinson's disease organoid and 3D culture | • The model utilized midbrain neural floor plate progenitors cells to generate 3D organoids of the human midbrain with the LRRK2-G2019S mutation. | Smits and Schwamborn, 2020 |
| Parkinson's disease organoid and 3D culture | • Mutated organoids showed a decrease in the complexity and quantity of dopaminergic neurons. | Smits and Schwamborn, 2020 |
| Parkinson's disease organoid and 3D culture | • Mutated organoids showed a decrease in the complexity and quantity of dopaminergic neurons. | Smits and Schwamborn, 2020 |
| Parkinson's disease organoid and 3D culture | • Review focusing on the successes of myelination, synapse formation, neuronal firing, network synchrony and overall architecture of the model necessary to allow for this. | Smits and Schwamborn, 2020 |
| Parkinson's disease organoid and 3D culture | • The first successful generation of a midbrain organoid model of idiopathic PD. | Chliebanowska et al., 2020 |
| Parkinson's disease organoid and 3D culture | • Mononuclear blood cells were used to generate iPSCs and differentiated into an organoid-like model. | Chliebanowska et al., 2020 |
| Parkinson's disease organoid and 3D culture | • PD neuronal cells showed varied expression levels of LIM homeobox transcription factor-alpha in early development and modified tyrosine hydroxylase levels in late development. | Chliebanowska et al., 2020 |
| Parkinson's disease multi-system organoid | • Highlighting the need for multi-organ systems, encompassing multiple brain regions, immune cells, the gut, and intestines, to study Parkinson’s disease. | Reiner et al., 2021 |
| Parkinson's disease multi-system organoid | • Arguing that the signs of PD initially show in the gut prior to any neurologic deficits. | Reiner et al., 2021 |

3D: Three-dimensional; FOXA2: Forkhead Box A2; LRRK2: leucine-rich repeat kinase 2; PD: Parkinson’s disease.
Table 7 | A summary of neurological cell-based iPSC models for AD

| Neurological disorder | Model and mutation | Purpose and findings of model | Reference |
|-----------------------|--------------------|------------------------------|-----------|
| Alzheimer’s disease   | Fibroblast derived iPSCs – FAD PSEN1 mutation A246E and PS2 (N141I) | • These iPSC-derived neurons have an elevated amyloid-beta 42:40. • Gamma-secretase modulators and inhibitors successfully mitigated any significant increase in expression of amyloid-beta. | Yagi et al., 2011 |
| Alzheimer’s disease   | Fibroblast derived iPSCs- various | • Testing anti-amyloid beta drugs on neurons derived from various Alzheimer’s iPSC. • Showing successful inhibition of amyloid-beta production by β-secretase inhibitors, γ-secretase inhibitors, and an NSAID. • iPSC-derived neuronal cells were capable of expressing functional β- and γ-secretases and releasing amyloid-beta peptide. | Yahata et al., 2011 |
| Alzheimer’s disease   | Fibroblast derived iPSCs – trisomy of chromosome 21 (Down syndrome) | • iPSCs from patients with Trisomy 21 were differentiated into cortical neurons. • These cortical neurons generated neurofibrillary tangles of hyperphosphorylated tau protein and aggregates of amyloid peptides. • A gamma-secretase inhibitor successfully blocked the production of amyloid-beta peptides. | Shi et al., 2012 |
| Alzheimer’s disease   | Fibroblast derived iPSCs – sporadic and APP duplication familial AD | • Two FAD models and one sporadic iPSC model showed increased levels of pathological markers active glycogen synthase kinase-3β (gSK-3β), phospho-tau (Thr231), and amyloid-β (1–40). • Treatment with beta-secretase inhibitors reduced Thr231 and gSK-3β levels. • The model was the first to show a direct relationship between tau phosphorylation, gSK-3β activation, and APP proteolytic processing in human neurons. | Israel et al., 2012 |
| Alzheimer’s disease   | Fibroblast derived iPSCs – (APP)-E693D mutation and sporadic AD | • Through differentiation of iPSCs derived from familial and sporadic AD patients, the researchers demonstrated the accumulation of amyloid-beta oligomers in neurons and astrocytes. • The ER stress response generated in AD neural cells was alleviated with the treatment of docosahexaenoic acid. • Demonstrating the possibility to trial the novel therapeutic in a subset of AD patients. | Kondo et al., 2013 |
| Alzheimer’s disease   | Fibroblast derived iPSCs – FAD PSEN1 mutation A246E | • PSEN1 mutant iPSCs mimicked the biochemical features of AD, indicated by an β-amyloid (AB)42/AB40 ratio. • Concluded that iPSC models of AD can help to test diagnostic methods and therapeutics. | Mahairaki et al., 2014 |
| Alzheimer’s disease   | Fibroblast derived iPSCs – APOE3 and APOE4 – sporadic AD | • The model generated iPSC-derived basal forebrain cholinergic neurons. • These neurons had an increased amyloid-beta 42:40 ratio, characteristic of AD. • Gamma-secretase inhibitors modulated decreased pathological levels of amyloid-beta. • Demonstrating increased vulnerability of glutamate-mediated cell death in association with increased intracellular free calcium. | Duan et al., 2014 |
| Alzheimer’s disease   | Fibroblast derived iPSCs – London familial AD mutation V717I | • Demonstrating increases in APP expression and amyloid-beta protein, total tau, and phosphorylated tau in the London familial AD model V717I. • Showing that the APPV717I mutation affects both β- and γ-secretase cleavage of APP. • Successful reduction of total tau and altered amyloid-beta production were demonstrated using amyloid-beta-specific antibodies. | Muratore et al., 2014 |
| Alzheimer’s disease   | Fibroblast derived iPSCs – A673T APP mutation conferring protection against the development of AD | • Identifying an APP variant (A673T) that confers protection against the development of AD. • The altered APP substrate is less favorable for cleavage by the BACE1 enzyme. • Showing reduced levels of amyloid-beta peptides and decreases in amyloid-beta degradation. | Maloney et al., 2014 |
| Alzheimer’s disease   | Fibroblast derived iPSCs – PSEN1 mutation | • Presenilin 1 (PSEN1) encodes the catalytic subunit of γ-secretase • PSEN1 mutated neural progenitor cells demonstrated an increased amyloid-beta 42/40. • 14 genes were differentially expressed in FAD mutant with 5 of these showing differential expression in pathology samples of the human brain. • These may serve as targets for therapeutics in patients with AD. | Sproul et al., 2014 |
| Alzheimer’s disease   | Fibroblast derived iPSCs – trisomy of chromosome 21 (Down syndrome), PSEN1 mutation, and amyloid precursor protein duplication | • Secretomes from all models showed inhibition of hippocampal long-term potentiation in a rat brain. • Synaptic dysfunction caused by PSEN1 mutation and APP duplication is modulated by amyloid-beta peptides. • This model shows the pathophysiology underlying cases of inherited AD. | Hu et al., 2018 |

Table 8 | Neurological 3D models for Alzheimer’s disease

| Neurologic organoids and 3D culture | Structures replicated | Reference |
|-------------------------------------|----------------------|-----------|
| Alzheimer’s disease neural 3D model | • Establishing a familial Alzheimer’s disease 3D model through human neural derived stem cells. • Using beta & gamma secretase-inhibitors to decrease levels of beta-amyloid and tau protein in the classical presentation of Alzheimer’s disease. | Choi et al., 2014 |
| Alzheimer’s disease cerebral organoid model | • Two models of AD cerebral iPSC-derived organoids were generated from patients with familial AD and patients with down-syndrome. • Showing pathologic accumulation of amyloid-beta peptides and creating in vitro structures that resembled amyloid plaques. • Generating structures similar to neurofibrillary tangles from in vivo samples of patients with AD. | Gonzalez et al., 2018 |
| 3D human triculture of Alzheimer’s disease | • 3D model of Alzheimer’s disease utilizing the simultaneous culture of microglia, neurons, and astrocytes in a 3D microfluidic platform. • Novel in its ability to mimic neurotoxic activities, including axonal cleavage, microglial recruitment to inflammation, and nitric oxide release that damage neurons and astrocytes. | Park et al., 2018 |

AD: Alzheimer’s disease; Apo: apolipoprotein; APP: amyloid-beta precursor protein; BACE1: beta-site APP cleaving enzyme 1; ER: endoplasmic reticulum; FAD: familial Alzheimer’s disease; iPSC: induced pluripotent stem cell; PSEN/PS: presenilin.
These models displayed neuroanomia and many characteristics of a blood-brain barrier. These vascularized organoids matured more quickly and theoretically provide a much more accurate model of normal physiology.

In the aging-related diseases (e.g., AD and PD) that rely on proper modeling, it is difficult to mimic the multiple genetic alterations that occur in the transcriptomic profile over time (López-Otín et al., 2013). In iPSC models, we try to drive cells back to an undifferentiated state, making it difficult to access the markers of maturity and expression while simultaneously driving cells back in their lineage (Gerakis and Hertz, 2019). This makes it difficult to mimic age-related iPSC models.

Another complication of iPSCs is that somatic cell reprogramming is extensively linked to genomic instability, especially at known tumorigenic loci (Maysahr et al., 2010). In modeling human disease in organoid models, it is essential to minimize and hopefully eliminate any undesired genetic mutations to accurately recapitulate the disease of interest.

A final limitation that has recently been overcome in organoid models is appropriate modeling and incorporation of immune cells into brain organoids (Yakoub, 2019). Without microglia, which originate directly from the yolk sac, models may not be able to fully recapitulate the normal architecture and cells of the CNS (Ginhoux and Prinz, 2015; Perdiguero et al., 2015). Emerging advancements in the field show the potential for mesodermal progenitors to develop into microglia-like cells (Ormel et al., 2018). As new models continue to emerge with microglia-containing cerebral organoids (Bodnar et al., 2021; Xu et al., 2021), we can begin to mimic the in vivo physiology more closely and hopefully, advance better understanding the pathological mechanisms of neurodegenerative disorders.

Future Directions

Through cell-based models, researchers can get a better understanding of the pathophysiology of neurological disorders. In vitro modeling can allow for the study of normal and abnormal physiological conditions. Organoids offer researchers another level of depth in approaching embryology and the etiology of both congenital and acquired diseases. As our understanding of these diseases grows, we may begin to further stratify the pathology and develop the process of having more personalized medicine to refine our therapeutic approach to neurological disorders.

Organel development for the neurological system is relatively new for the purpose of recapitulating the multilevel processes that are damaged throughout the course of these disorders. For example, in PD we are seeing the transplantation of functional and genetically corrected dopaminergic neurons that are capable of providing dopamine to another level of depth in approaching embryology and the etology of both congenital and acquired diseases. As our understanding of these diseases grows, we may begin to further stratify the pathology and develop the process of having more personalized medicine to refine our therapeutic approach to neurological disorders.

As cell-based models begin to evolve into more organoid and 3D-based model approaches, we will eventually be able to mimic the pathophysiology of the disease, elucidate the etiologies that underpin the phenotypes of these diseases, and, hopefully, advance novel drug therapies that one day may lead to a cure for various neurological disorders.

Acknowledgments: We are thankful to Dr. Valerie Gramling from the Department of English, University of Miami, Coral Gables, FL, USA for critical reading of the manuscript.

Author contributions: All authors contributed to conceptualization, writing, reviewing, editing and proofing the manuscript, and approved the final version of the manuscript.

Conflicts of interest: The authors declare no conflict of interest.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons AttributionNonCommercial-ShareAlike 4.0 License, which allows others to remix, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

References

Acb A, Mootri AR (2015) The use of induced pluripotent stem cell technology to advance autism research and treatment. Neurotherapeutics 12:534-545.

Adler C, Sethi KD, Hauser R, Davis T, Hammerstad J, Berton J, Taylor R, Sanchez-Ramos J, O’Brien C, Group RG (1997) Rosiglitazone for the treatment of early Parkinson’s disease. The Parkinson’s Study Group. NEURON REGENERATION RESEARCH www.nrronline.org

Ball N, Teo WP, Chandra S, Chapman J (2019) Parkinson’s disease and the environment. Nature 515:274-276.

Choi SH, Kim YH, Moksh M, Sliwinski C, Lee S, Davanzo C, Chen H, Hooi B, Auscell C, Muffat J (2014) A three-dimensional human neural cell culture model of Alzheimer’s disease. Nature 12:2048-2057.

Devi MJ, Ryder M, Vodick P, Thomson AJ, Burdon T, Houlden H, Cavaletti F, Nagano M, Drummond MM, Taanman JW (2011) Parkinson’s disease induced pluripotent stem cells with triplication of the α-synuclein locus. Nat Commun 3:1-17.

D’Ulio L, Kriegstein AR (2017) The use of brain organoids to investigate neural development and disease. Nat Rev Neurosci 18:573.

Dicarlo GE, Aguilar JJ, Matthews H, Harrison FE, Beckey KS, West A, Hashemi PH, Herborg F, Rickag M, Chen H (2020) Autism-linked dopamine transporter mutation alters spontaneous neurotransmitter and dopamine-dependent behaviors. J Clin Invest 129:3407-3419.

Dimos JT, Rodolfa KT, Niakan KK, Weissenthal LM, Mitsumori H, Chung W, Croft GF, Saphier G, Leibel R, Goland R (2008) Induced pluripotent stem cells generated from patients with adult-onset diabetes can be differentiated into functional islet cells. Science 321:190-193.

Duan L, Bhattacheravy BJ, Belmadani A, Pan I, Miller RJ, Kessler JA (2015) Stem cell derived basal forebrain cholinergic neurons from Alzheimer’s disease patients are more susceptible to cell death. Mol Neurodegener 9:1-14.

Eshraghi AA, Liu G, Kay SIS, Eshraghi RS, Mittal J, Moshiree B, Mittal R (2015) Epigenetics and Autism spectrum disorder: is there a correlation? Front Neurosci 9:278.

Fink J, Schiermeyer ID, Bloom JM, Baker DR, Robinson LM, Lijnen HR, Lemon M, Chamberlin SJ, Levine ES (2018) Hyperexcretable phenotypes in iPSC-derived neurons from patients with 15q11-13 duplication syndrome, a genetic form of autism. Biol Psychiatry doi:10.1016/j.biopsych.2017.08.020.

Fiorentino M, Sapone A, Senger S, Cammar C, Sandesi KM, Buie TM, Kelly DL, Casella C, Nasano A (2016) Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. Mol Autism 7:1-31.

Frotscher M (1998) Cajal—retzius cells, reelin, and the formation of layers. Curr Opin Neurobiol 8:570-575.

Fujimoto K, Ishikawa M, Otsomo A, Asuta N, Nakamura R, Aktyama T, Hdadano S, Aoki M, Saya H, Sobeja G (2018) Modeling sporadic and familial alzheimer’s disease using induced pluripotent stem cells. Nature 482:216-220.

Ginhoux F, Prinz A (2015) Origin of microglia: current concepts and past controversies. Cold Spring Harb Perspect Biol 7:A020537.

Goedert M, Spillantini MG (2006) A century of Alzheimer’s disease. Science 314:777-781.

Gonzalez-Bonilla M, Amojo E, Bravo-Alegria L, Nistora-Calillo A, Mays C, Soto C (2018) Modeling amyloid beta and tau pathology in human neural organoids. Mol Psychiatry 23:2363-2374.

Gouder L, Vitrac A, Goubert-Bottos H, Danckaert A, Tienneur J, André-Leroux G, Aratanev E, Lemarre N, Biton A, Leblond ES (2013) Altered sponginess in iPSC-derived cortical neurons from patients with autism carrying De Novo Shank3 Mutations. Sci Rep 9:1-11.

Grebenyuk S, Ranga A (2019) Engineered organoid vascular organization. Front Bioeng Biotechnol 7:319.

Griess-Oliveira K, Fago M, Pinto B, Alves A, Suzuki A, Morales A, Equina S, Sosa O, Sutton G, Sunaga-Franco D (2020) Transcriptome of iPSC-derived neuronal cells reveals a module of co-expressed genes consistently associated with autism spectrum disorder. Mol Psychiatry 4:71-87.

Harris J, Tomass Y, Arlotta P (2015) Building blocks of the cerebral cortex: from development to the dish. Wiley Interdiscip Rev Dev Biol 4:529-544.

Hodges J, Fea E, Ceall M, Newell N, Robinson LM, Lijnen HR, Sierra-Calillo A, Mays C, Soto C (2018) Modeling amyloid beta and tau pathology in human neural organoids. Mol Psychiatry 23:2363-2374.

Hyung M, Auel J, North DN, Barski A, Linskens F, Watanabe K, Wiris J, Rothermel K, Fineberg H, Beck MM, Lu H, Cao Y, Zhang J, Nebel J, Li H, Xin X, Wang H, Chen H, Hooli B, Asselin C, Muffat J (2020) A three-dimensional human neural cell culture model of Autism spectrum disorder. Cell Rep 21:2678-2687.

Jiang H, Ren Y, Yuen EY, Zhong P, Ghaedi M, Hu Z, Azabdaftari G, Nakaso K, Yan Z, Feng J (2012) A model of Autism spectrum disorder from induced pluripotent stem cells. Front Cell Neurosci 15:682272.
